Effect of epidural dexmedetomidine on post-operative nausea & vomiting in adult patients undergoing abdominopelvic surgery: a randomized controlled study.
{"title":"Effect of epidural dexmedetomidine on post-operative nausea & vomiting in adult patients undergoing abdominopelvic surgery: a randomized controlled study.","authors":"Piyawan Koopredechat, Wanida Chongarunngamsang, Manita Kaweewong, Nattamon Thitipanichayankul, Salinee Poonjan, Thanyalak Chanakul","doi":"10.1186/s12871-025-03324-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The incidence of postoperative nausea and vomiting (PONV) has been reported to reach as high as 33.5% in patients undergoing abdominal surgeries. Intravenous dexmedetomidine has been shown to be effective in reducing the incidence of PONV, possibly through the inhibition of catecholamine release and decreased opioid requirements. This study aims to investigate the potential efficacy of epidural dexmedetomidine in preventing PONV in patients undergoing abdominal and pelvic surgery under combined general-epidural anesthesia.</p><p><strong>Methods: </strong>The study enrolled patients aged 18-65 years with an ASA physical status I-III who were scheduled for elective open abdominal or pelvic surgery. Patients were randomized to receive either a single bolus dose of dexmedetomidine during peritoneal closure or placebo. No additional PONV prophylaxis was provided. Patients in the dexmedetomidine group received 2 mg of morphine combined with dexmedetomidine 1 mcg kg<sup>-1</sup> via the epidural catheter, whereas those in the placebo group received only morphine diluted to an equivalent volume.</p><p><strong>Results: </strong>Of the 108 patients randomized between August 2024 to April 2025, 99 were included in the final analysis. The incidence of PONV within 1 and 6 h postoperatively was significantly lower in the dexmedetomidine group compared to placebo (3.8% vs. 30.4%; RR 0.12, 95% CI 0.03-0.52, p < 0.001 and 13.2% vs. 32.6%, RR 0.41, 95% CI 0.18-0.91, p = 0.021), respectively. The severity of postoperative nausea was not different between the groups (p = 0.557). The incidence of postoperative shivering was significantly lower in the dexmedetomidine group (0% vs. 15.2%, p = 0.003).</p><p><strong>Conclusions: </strong>A single administration of epidural dexmedetomidine at 1 mcg kg<sup>-1</sup> significantly reduced both the incidence of early PONV at 1 and 6 h postoperatively and postoperative shivering without increasing hemodynamic complications.</p><p><strong>Clinical trial registration: </strong>Retrospectively registered with Thai Clinical Trials Registry (TCTR20250331001) on 31 March 2025.</p>","PeriodicalId":9190,"journal":{"name":"BMC Anesthesiology","volume":"25 1","pages":"430"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382251/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Anesthesiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12871-025-03324-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The incidence of postoperative nausea and vomiting (PONV) has been reported to reach as high as 33.5% in patients undergoing abdominal surgeries. Intravenous dexmedetomidine has been shown to be effective in reducing the incidence of PONV, possibly through the inhibition of catecholamine release and decreased opioid requirements. This study aims to investigate the potential efficacy of epidural dexmedetomidine in preventing PONV in patients undergoing abdominal and pelvic surgery under combined general-epidural anesthesia.
Methods: The study enrolled patients aged 18-65 years with an ASA physical status I-III who were scheduled for elective open abdominal or pelvic surgery. Patients were randomized to receive either a single bolus dose of dexmedetomidine during peritoneal closure or placebo. No additional PONV prophylaxis was provided. Patients in the dexmedetomidine group received 2 mg of morphine combined with dexmedetomidine 1 mcg kg-1 via the epidural catheter, whereas those in the placebo group received only morphine diluted to an equivalent volume.
Results: Of the 108 patients randomized between August 2024 to April 2025, 99 were included in the final analysis. The incidence of PONV within 1 and 6 h postoperatively was significantly lower in the dexmedetomidine group compared to placebo (3.8% vs. 30.4%; RR 0.12, 95% CI 0.03-0.52, p < 0.001 and 13.2% vs. 32.6%, RR 0.41, 95% CI 0.18-0.91, p = 0.021), respectively. The severity of postoperative nausea was not different between the groups (p = 0.557). The incidence of postoperative shivering was significantly lower in the dexmedetomidine group (0% vs. 15.2%, p = 0.003).
Conclusions: A single administration of epidural dexmedetomidine at 1 mcg kg-1 significantly reduced both the incidence of early PONV at 1 and 6 h postoperatively and postoperative shivering without increasing hemodynamic complications.
Clinical trial registration: Retrospectively registered with Thai Clinical Trials Registry (TCTR20250331001) on 31 March 2025.
背景:据报道,腹部手术患者术后恶心呕吐(PONV)发生率高达33.5%。静脉注射右美托咪定可能通过抑制儿茶酚胺的释放和减少阿片类药物的需求来有效降低PONV的发生率。本研究旨在探讨硬膜外右美托咪定在全身硬膜外联合麻醉下预防腹部和骨盆手术患者PONV的潜在疗效。方法:研究纳入年龄在18-65岁,ASA身体状态为I-III的患者,这些患者计划择期进行腹部或骨盆开放手术。患者在腹膜闭合期间随机接受单剂量右美托咪定或安慰剂。没有提供额外的PONV预防。右美托咪定组患者通过硬膜外导管接受2mg吗啡联合右美托咪定1mcg kg-1,而安慰剂组患者仅接受等量稀释的吗啡。结果:在2024年8月至2025年4月随机抽取的108例患者中,99例纳入最终分析。与安慰剂组相比,右美托咪定组术后1和6小时内PONV的发生率显著降低(3.8% vs. 30.4%; RR 0.12, 95% CI 0.03-0.52, p)。结论:单次硬膜外给药1 mcg kg-1右美托咪定可显著降低术后1和6小时早期PONV的发生率和术后发抖发生率,且未增加血流动力学并发症。临床试验注册:于2025年3月31日在泰国临床试验注册中心(TCTR20250331001)回顾性注册。
期刊介绍:
BMC Anesthesiology is an open access, peer-reviewed journal that considers articles on all aspects of anesthesiology, critical care, perioperative care and pain management, including clinical and experimental research into anesthetic mechanisms, administration and efficacy, technology and monitoring, and associated economic issues.